Press Releases

Date Title and Summary Additional Formats
Toggle Summary Argos Announces Receipt of Milestone Payment from Lummy (Hong Kong) Co. Ltd.
DURHAM, N.C., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today announced receipt of a $1.5
View HTML
Toggle Summary Argos Therapeutics to Report Third Quarter 2017 Financial Results and Operational Highlights on Thursday, November 9, 2017
DURHAM, N.C., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today announced that the Company
View HTML
Toggle Summary Argos Therapeutics Announces Appointment of Richard Morrison, PhD to Board of Directors
DURHAM, N.C., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today announced the appointment of
View HTML
Toggle Summary Argos Therapeutics to Hold Conference Call to Discuss Update on the Phase 3 ADAPT Trial Presented at the ESMO 2017 Congress
DURHAM, N.C., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis ® precision immunotherapy technology platform, will hold a conference call to
View HTML
Toggle Summary Argos Therapeutics Reports on Interim Analysis of Phase 3 ADAPT Trial Presented at ESMO 2017 Congress
DURHAM, N.C., Sept. 12, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today reported on an update on the
View HTML
Toggle Summary Argos Announces First Dosing of HIV Patient with AGS-004 Derived from the Latent Viral Reservoir
New Manufacturing Process Utilizes Latent Viral RNA Antigens
View HTML
Toggle Summary Argos Therapeutics Announces Interim Analysis of Phase 3 ADAPT Trial to be Presented at ESMO 2017 Congress
DURHAM, N.C., Aug. 21, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today announced that an interim
View HTML
Toggle Summary Argos Therapeutics Reports Second Quarter 2017 Financial Results and Recent Operational Highlights
- Announced Continuation of the ADAPT Trial following Meeting with the FDA - - Raised Gross Proceeds of $6.0 million in Secured Convertible Note Financing - - Reported Positive Immunogenicity Data in AGS-004 Program for the Treatment of HIV - DURHAM, N.C., Aug.
View HTML
Toggle Summary Argos Reports Immunogenicity Results of AGS-004 in HIV Program
DURHAM, N.C., July 26, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis ® precision immunotherapy technology platform, today announced immunogenicity
View HTML
Toggle Summary Argos Therapeutics Announces Closing of $6.0 Million Secured Convertible Note Financing
DURHAM, N.C., June 22, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis® technology platform, today
View HTML

Stock Quote

Copyright West LLC. Minimum 15 minutes delayed.

Tweets